Penetrium Bioscience페니트리움바이오
187660 · KOSDAQ · ₩187660 · 페니트리움바이오
- Market cap
- ₩426B
- Enterprise value
- ₩431B
- P/E
- —
- P/B
- 18.6×
- Dividend yield
- 0.0%
- ROE
- −71.3%
- Net margin
- −196.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−69.0% from the high
₩2,325Today: ₩6,400 – ₩6,810₩21,500
Returns
- 1W+16.4%
- 1M−2.6%
- 3M+73.0%
- 6M−45.0%
- YTD+179.8%
- 1Y+127.3%
- Volume today
- 843,412
- 1.1× the 20-day average
- Traded today
- ₩5.6B
- Listed shares
- 63,966,253
- EPS (12 months)
- −₩256
- Earnings yield −3.8%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
- MomentumFlat0.5% over the last month; the price is above its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Penetrium Bioscience stock overview
Penetrium Bioscience (페니트리움바이오, KRX: 187660) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean contract research organization (CRO) that provides clinical trial services, including trial design, execution, data management, regulatory support and drug safety monitoring, to pharmaceutical companies and biotech ventures. Its shares closed at ₩6,660 on Oct 28, 2026, up 4.88% on the day, giving it a market value of ₩426B.
Key facts
- Market cap
- ₩426B
- Sector
- Biotech & Pharma
- Latest price change
- +4.88%
- As of
- Oct 28, 2026
- Main business
- The company is a Korean contract research organization (CRO) that provides clinical trial services, including trial design, execution, data management, regulatory support and drug safety monitoring, to pharmaceutical companies and biotech ventures.
Quick answers about Penetrium Bioscience
- What does Penetrium Bioscience do?
- The company is a Korean contract research organization (CRO) that provides clinical trial services, including trial design, execution, data management, regulatory support and drug safety monitoring, to pharmaceutical companies and biotech ventures. It also runs Phase 4 late-phase studies such as post-marketing surveillance and real-world evidence work, and is developing cancer drug technology in breast and lung cancer, with its sales mostly in South Korea.
- What is the market cap of Penetrium Bioscience?
- The market capitalisation of Penetrium Bioscience was ₩426B at the close on Oct 28, 2026.
- Who are the largest shareholders of Penetrium Bioscience?
- According to the latest official filings, the largest reported holders are Hyundai Bio (37.57%, as of Oct 14, 2026); Park Cha-seok (0.09%, as of Oct 19, 2026).
- When is the next earnings report from Penetrium Bioscience?
- Korean companies rarely announce results dates in advance. Based on when Penetrium Bioscience filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company is a Korean contract research organization (CRO) that provides clinical trial services, including trial design, execution, data management, regulatory support and drug safety monitoring, to pharmaceutical companies and biotech ventures. It also runs Phase 4 late-phase studies such as post-marketing surveillance and real-world evidence work, and is developing cancer drug technology in breast and lung cancer, with its sales mostly in South Korea.
Written by AI from the company's latest annual report.
- Korean name
- 페니트리움바이오
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 조원동, 진근우(공동 대표이사)
- Founded
- Oct 2003
- Listed
- Jun 2021
- Listed shares
- 63,966,253
- Fiscal year ends
- Month 12
- Website
- hdadmbio.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Insider shareholding reportOct 19, 2026
- 5%+ holding reportOct 14, 2026
- 5%+ holding reportSep 9, 2026
- Amended: 5%+ holding reportSep 9, 2026
- 5%+ holding reportSep 4, 2026
Titles in Korean until English translations are added.
Also known as: Penetrium Bioscience / 페니트리움바이오 / 187660 / KRX:187660
Source: KRX statistical information